These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7910053)

  • 1. Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection.
    Garaci E; Rocchi G; Perroni L; D'Agostini C; Soscia F; Grelli S; Mastino A; Favalli C
    Int J Clin Lab Res; 1994; 24(1):23-8. PubMed ID: 7910053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
    Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
    J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus symposium on combined antiviral therapy; overview of interferon and IL-2 combinations for the treatment of HIV infection.
    Sneller MC
    Antiviral Res; 1996 Jan; 29(1):105-9. PubMed ID: 8721559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S73-5. PubMed ID: 15546254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection.
    Davey RT; Davey VJ; Metcalf JA; Zurlo JJ; Kovacs JA; Falloon J; Polis MA; Zunich KM; Masur H; Lane HC
    J Infect Dis; 1991 Jul; 164(1):43-52. PubMed ID: 1676045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; van der Ende ME; ten Napel CH; Weigel HM; Schreij GS; Kauffmann RH; Koopmans PP; Hoepelman AI; de Boer JB; Weverling GJ
    J Infect Dis; 1994 Jun; 169(6):1351-5. PubMed ID: 7910838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
    Krown SE; Gold JW; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew BJ
    Ann Intern Med; 1990 Jun; 112(11):812-21. PubMed ID: 1971504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells.
    Moshier JA; Mutchnick MG; Dosescu J; Holtz TK; Akkary S; Mahakala K; Merline JR; Naylor PH
    J Hepatol; 1996 Dec; 25(6):814-20. PubMed ID: 9007707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
    Krown SE; Aeppli D; Balfour HH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma.
    Bazarbachi A; Nasr R; El-Sabban ME; Mahé A; Mahieux R; Gessain A; Darwiche N; Dbaibo G; Kersual J; Zermati Y; Dianoux L; Chelbi-Alix MK; de Thé H; Hermine O
    Leukemia; 2000 Apr; 14(4):716-21. PubMed ID: 10764160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
    Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
    Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B.
    Lim SG; Wai CT; Lee YM; Dan YY; Sutedja DS; Wee A; Suresh S; Wu YJ; Machin D; Lim CC; Fock KM; Koay E; Bowden S; Locarnini S; Ishaque SM
    Antivir Ther; 2006; 11(2):245-53. PubMed ID: 16640105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymalfasin: an immune system enhancer for the treatment of liver disease.
    Sjogren MH
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S69-72. PubMed ID: 15546253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.
    Fischl MA; Richman DD; Saag M; Meng TC; Squires KE; Holden-Wiltse J; Meehan PM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Dec; 16(4):247-53. PubMed ID: 9402071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection.
    Lane HC; Zunich KM; Wilson W; Cefali F; Easter M; Kovacs JA; Masur H; Leitman SF; Klein HG; Steis RG
    Ann Intern Med; 1990 Oct; 113(7):512-9. PubMed ID: 1975487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance and response related factors.
    Del Pozo MA; Arias JR; Pinilla J; Labarga P; Alcoba M; Martinez de la Cruz FJ; Anton F; Carro JA; Perez MR; Echevarria S; Garrote E; Moreno-Otero R
    Hepatogastroenterology; 1998; 45(23):1695-701. PubMed ID: 9840131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study.
    Wood R; Montoya JG; Kundu SK; Schwartz DH; Merigan TC
    J Infect Dis; 1993 Mar; 167(3):519-25. PubMed ID: 8095058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between thymic hormones and other immunomodulatory agents.
    Mastino A; Favalli C; Grelli S; Garaci E
    Ann Ist Super Sanita; 1991; 27(1):51-6. PubMed ID: 1958028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.